Highly efficient therapeutic gene editing of human hematopoietic stem cells

Journal: Nature Medicine

Published: 2019-03-25

DOI: 10.1038/s41591-019-0401-y

Affiliations: 16

Authors: 24

Go to article
Institutions Share
Broad Institute of MIT and Harvard, United States of America (USA) 0.17
Division of Hematology/Oncology, BCH, United States of America (USA) 0.14
Department of Pediatric Oncology, DFCI, United States of America (USA) 0.14
Harvard Stem Cell Institute (HSCI), United States of America (USA) 0.14
Department of Molecular, Cell and Cancer Biology (MCCB), UMass Medical School, United States of America (USA) 0.08
Li Weibo Institute for Rare Diseases Research, UMass Medical School, United States of America (USA) 0.08
Department of Hematology, St. Jude, United States of America (USA) 0.08
Dana-Farber/Boston Children's Cancer and Blood Disorders Center, United States of America (USA) 0.03
Pathology Research Center - Molecular Pathology Unit, MGH, United States of America (USA) 0.03
Center for Cancer Research, MGH, United States of America (USA) 0.03
Center for Computational and Integrative Biology (CCIB), MGH, United States of America (USA) 0.03
Department of Pathology, BWH, United States of America (USA) 0.02
Harvard Department of Pathology, United States of America (USA) 0.02
Shanghai Key Laboratory of Regulatory Biology, ECNU, China 0.01
UCL Great Ormond Street Institute of Child Health (ICH), United Kingdom (UK) 0.01

Return

Except where otherwise noted © 2019 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER